Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 12 | 2024 | 21206 | 1.010 |
Why?
|
| BRCA2 Protein | 2 | 2020 | 802 | 0.970 |
Why?
|
| Glutaminase | 1 | 2023 | 31 | 0.880 |
Why?
|
| BRCA1 Protein | 2 | 2020 | 1155 | 0.860 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2017 | 79 | 0.570 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2024 | 1099 | 0.540 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 789 | 0.450 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2015 | 354 | 0.400 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2015 | 565 | 0.380 |
Why?
|
| Cerebellar Ataxia | 1 | 2012 | 151 | 0.360 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2012 | 154 | 0.360 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 1536 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 2830 | 0.340 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2012 | 454 | 0.280 |
Why?
|
| Brain Diseases | 1 | 2014 | 1554 | 0.240 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2565 | 0.240 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 13586 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 5703 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 3671 | 0.220 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 3409 | 0.210 |
Why?
|
| Brain Neoplasms | 1 | 2024 | 9118 | 0.210 |
Why?
|
| Oxadiazoles | 1 | 2021 | 94 | 0.190 |
Why?
|
| Mutation | 3 | 2021 | 30238 | 0.190 |
Why?
|
| Prognosis | 4 | 2023 | 30010 | 0.180 |
Why?
|
| Neoplasms | 3 | 2021 | 22371 | 0.180 |
Why?
|
| Atrial Flutter | 1 | 2023 | 253 | 0.180 |
Why?
|
| Trophoblasts | 1 | 2022 | 223 | 0.180 |
Why?
|
| Receptor, trkA | 1 | 2021 | 159 | 0.180 |
Why?
|
| Piperazines | 4 | 2020 | 2554 | 0.180 |
Why?
|
| Glutamine | 1 | 2023 | 577 | 0.180 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2023 | 273 | 0.170 |
Why?
|
| Gene Expression | 2 | 2023 | 7598 | 0.160 |
Why?
|
| Fatal Outcome | 1 | 2024 | 1836 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2023 | 528 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 13676 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9419 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 259 | 0.150 |
Why?
|
| Antigens, Surface | 1 | 2022 | 1617 | 0.150 |
Why?
|
| Phthalazines | 1 | 2020 | 397 | 0.140 |
Why?
|
| Female | 16 | 2024 | 397192 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 5717 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2020 | 5341 | 0.140 |
Why?
|
| Osteoprotegerin | 1 | 2017 | 179 | 0.130 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 4912 | 0.130 |
Why?
|
| Nitriles | 1 | 2021 | 980 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 2022 | 1613 | 0.130 |
Why?
|
| Germ Cells | 1 | 2020 | 644 | 0.130 |
Why?
|
| RANK Ligand | 1 | 2017 | 321 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 581 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1105 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 1997 | 0.110 |
Why?
|
| Humans | 21 | 2024 | 768166 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 952 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2021 | 975 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 1613 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 11244 | 0.100 |
Why?
|
| Drug Design | 1 | 2017 | 1046 | 0.100 |
Why?
|
| Receptors, Estrogen | 2 | 2017 | 2253 | 0.100 |
Why?
|
| Biopsy | 1 | 2024 | 6793 | 0.100 |
Why?
|
| Purines | 1 | 2015 | 615 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1791 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4120 | 0.100 |
Why?
|
| Stroke | 1 | 2014 | 9755 | 0.100 |
Why?
|
| Aminopyridines | 1 | 2015 | 580 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 6847 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2021 | 2028 | 0.090 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 2120 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 2062 | 0.090 |
Why?
|
| Pyridines | 3 | 2019 | 2894 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2015 | 864 | 0.090 |
Why?
|
| Middle Aged | 8 | 2024 | 223492 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2021 | 3048 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 13014 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 3800 | 0.080 |
Why?
|
| Mastectomy | 1 | 2017 | 1861 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 3556 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 4833 | 0.070 |
Why?
|
| Genotype | 1 | 2021 | 13045 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 2907 | 0.060 |
Why?
|
| Sonication | 1 | 2006 | 79 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2015 | 1944 | 0.060 |
Why?
|
| Apoptosis | 1 | 2021 | 9523 | 0.060 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 5176 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12077 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 8647 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 17140 | 0.050 |
Why?
|
| Aged | 5 | 2021 | 171504 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 12543 | 0.050 |
Why?
|
| Logistic Models | 1 | 2017 | 13290 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9538 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 20760 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2006 | 1145 | 0.040 |
Why?
|
| Indazoles | 1 | 2021 | 306 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2020 | 81762 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 899 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2006 | 1288 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2021 | 905 | 0.030 |
Why?
|
| Benzamides | 1 | 2021 | 1379 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2006 | 1893 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 24315 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 40218 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 1120 | 0.030 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2006 | 1672 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2019 | 1095 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2017 | 23645 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2021 | 4030 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2457 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2016 | 519 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 1160 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 65371 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 757 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 74944 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15662 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 10760 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2016 | 1209 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 2954 | 0.020 |
Why?
|
| Male | 3 | 2023 | 364719 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 8054 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2016 | 2603 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2006 | 876 | 0.010 |
Why?
|
| Adult | 1 | 2015 | 223646 | 0.010 |
Why?
|
| Microscopy | 1 | 2006 | 909 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11878 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2023 | 54926 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 1667 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 36743 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2006 | 1967 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 19015 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2006 | 11669 | 0.000 |
Why?
|
Concepts
(129)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(34)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_